NCT04136834: A Phase I Open-label Study for Subjects With Advanced Malignancies

Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Phase 1
Drug Category: Misc Inhibitor

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Older Adult)
Location of Metastases: 
Additional Notes: Breast cancer patients are only eligible for the dose escalation phase of the study
Exclusions: Patients who received prior arginase or arginine deiminase therapy; Patients with symptomatic or uncontrolled brain metastases requiring current treatment

Comments are closed.

Up ↑